看帖神器
北美华人网
追帖动态
头条新闻
每日新帖
最新热帖
新闻存档
热帖存档
文学城
虎扑论坛
未名空间
北美华人网
北美微论坛
看帖神器
登录
← 下载
《看帖神器》官方
iOS App
,体验轻松追帖。
也算是老年痴呆症患者和患者家人的福音吧,FDA今天批准了新药
查看北美华人网今日新帖
最新回复:2023年1月6日 19点57分 PT
共 (2) 楼
返回列表
订阅追帖
只看未读
更多选项
阅读全帖
只看图片
只看视频
查看原帖
l
liucoan
接近 2 年
楼主 (北美华人网)
FDA Approves New Treatment for Early Alzheimer’s Story by Pam Belluck • 5h ago
The Food and Drug Administration on Friday approved a new Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease, but also carries risks of swelling and bleeding in the brain.
The newly approved drug, Leqembi, should be used only for patients in early and mild stages of Alzheimer’s disease, matching the status of patients in its clinical trials, the F.D.A. label says. © Zephyr/Science Source The approval of the drug, lecanemab, to be marketed as Leqembi, is likely to generate considerable interest from patients and physicians. Studies of the drug — an intravenous infusion administered every two weeks — suggest it is more promising than the scant number of other treatments available. Still, several Alzheimer’s experts said it was unclear from the medical evidence whether Leqembi could slow cognitive decline enough to be noticeable to patients.
M
MMitchell
接近 2 年
2 楼
只能在早期痴呆病人里用。只是有限地减缓了病情进展的速度而已。当然这次临床试验结果还是比上次的那个aduhelm要更靠谱一些。
请输入帖子链接
收藏帖子
The Food and Drug Administration on Friday approved a new Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease, but also carries risks of swelling and bleeding in the brain.
The newly approved drug, Leqembi, should be used only for patients in early and mild stages of Alzheimer’s disease, matching the status of patients in its clinical trials, the F.D.A. label says. © Zephyr/Science Source The approval of the drug, lecanemab, to be marketed as Leqembi, is likely to generate considerable interest from patients and physicians. Studies of the drug — an intravenous infusion administered every two weeks — suggest it is more promising than the scant number of other treatments available. Still, several Alzheimer’s experts said it was unclear from the medical evidence whether Leqembi could slow cognitive decline enough to be noticeable to patients.